Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers

Fig. 5

Mn2+ plus YM101 therapy promoted the transformation from immune-excluded to immune-inflamed tumors and enhanced immune cell infiltration in the EMT-6 model. a The representative flow cytometry images of tumor-infiltrating CD8+ T cells. b The representative flow cytometry images of tumor-infiltrating natural killer cells (NKs). c The representative images of α-CD3 staining in the tumor periphery and the tumor center. d The quantitative analysis for T cell number by integral fluorescence intensity. e The quantitative analysis for the depth of T cell infiltration (n = 5 biological replicates). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 denote the significant difference relative to Mn2+ plus YM101 therapy

Back to article page